Therapeutic Avelumab antibody from the original Bavencio® commercial drug.

Showing the single result

Filter our product list:
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Expiry Date
Filters Sort results
Reset Apply


Molecular Class
Drug Brand
Product Concentration
Quantity per vial
Storage Temperature
Expiry Date
Price from
Monoclonal Antibody
20 mg/mL
2 mg
view product
Max: 10
Min: 3
Step: 1

Not looking for Avelumab?

Search our therapeutic molecules product database

Bavencio® / Avelumab Reference Product

Drug nameBavencio®
API typeAvelumab is a human monoclonal IgG1 antibody directed against the immunomodulatory cell surface ligand protein PD-L1 and produced in Chinese hamster ovary cells by recombinant DNA technology.
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
Target of antibody
PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1,
Pdcd1lg1, Pdl1, RGD1566211
General functionAvelumab is used to treat adults with Merkel cell carcinoma (MCC), a rare type of skin cancer when it is metastatic (has spread to other parts of the body).
PD-L1 is found on the surface of MCC cells and helps protect tumour cells from the immune system (the body’s natural defences). Avelumab binds to PD-L1, and blocks this protective effect, allowing the immune system to attack the tumour cells. (Source EMA , package leaflet)
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Avelumab has also shown to induce natural killer (NK) cell-mediated direct tumour cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC).
Original license holder
Merck Europe B.V.
Marketing authorisation numbers
Marketing authorisation holder
Merck Europe B.V.
Gustav Mahlerplein 102
1082 MA Amsterdam
The Netherlands
Name of the manufacturer of the biological active substance
Merck Serono SA
Succursale de Corsier-sur-Vevey
Chemin du Fenil - Zone Industrielle B,
1804 Corsier-sur-Vevey
Name and address of the manufacturer(s) responsible for batch releaseMerck Serono S.p.A.
Via Delle Magnolie 15 (loc. frazione Zona Industriale)
70026 - Modugno (BA)
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Glacial acetic acid
Polysorbate 20
Sodium hydroxide